Amid accusations of inflating sales figures, New Horizon Health (HKG:6606) saw the resignation of Chairman and CEO Zhu Yeqing on Dec. 30, 2024, South China Morning Post reported.
The board also removed him as an executive director. Yao Naxin, a non-executive director, will now serve as board chairman, according to the report.
Earlier in 2024, the early cancer screening company's CFO and auditor also resigned following accusations from a short seller that New Horizon Health had inflated its 2022 sales figures.
Trading in the company's shares has been suspended since March 27, 2024, and will remain so until it meets resumption requirements, the publication said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。